byl719 and bicalutamide

byl719 has been researched along with bicalutamide* in 1 studies

Other Studies

1 other study(ies) available for byl719 and bicalutamide

Article	Year
Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report. JCO precision oncology, 2021, Volume: 5 Topics: Anilides; Antineoplastic Agents; Class I Phosphatidylinositol 3-Kinases; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Nitriles; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Thiazoles; Tosyl Compounds	2021

Article

Year

Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report.

JCO precision oncology, 2021, Volume: 5

Topics: Anilides; Antineoplastic Agents; Class I Phosphatidylinositol 3-Kinases; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Nitriles; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Thiazoles; Tosyl Compounds

2021